OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Bought by Factorial Partners LLC

Factorial Partners LLC lifted its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 12.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 339,953 shares of the medical instruments supplier’s stock after buying an additional 36,326 shares during the quarter. Factorial Partners LLC’s holdings in OraSure Technologies were worth $1,452,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of OraSure Technologies by 1.9% during the first quarter. Vanguard Group Inc. now owns 5,409,028 shares of the medical instruments supplier’s stock worth $33,266,000 after acquiring an additional 99,572 shares during the last quarter. Renaissance Technologies LLC grew its stake in OraSure Technologies by 20.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock valued at $9,749,000 after purchasing an additional 391,100 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of OraSure Technologies by 38.1% in the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after purchasing an additional 605,324 shares in the last quarter. Millennium Management LLC boosted its stake in shares of OraSure Technologies by 727.5% during the 2nd quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock valued at $8,610,000 after buying an additional 1,776,867 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of OraSure Technologies by 30.1% during the second quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock worth $7,710,000 after buying an additional 418,603 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on OSUR. StockNews.com raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 4th. Evercore ISI boosted their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research report on Wednesday, August 7th.

OraSure Technologies Price Performance

OraSure Technologies stock opened at $3.86 on Wednesday. OraSure Technologies, Inc. has a 12-month low of $3.72 and a 12-month high of $8.45. The firm has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $4.39. The stock has a market capitalization of $287.92 million, a PE ratio of 25.73 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $39.92 million for the quarter, compared to the consensus estimate of $38.97 million. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm’s revenue was down 55.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.27 earnings per share. On average, analysts forecast that OraSure Technologies, Inc. will post -0.09 earnings per share for the current fiscal year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.